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1. Introduction 
 
1.1 Perinatal asphyxia  
 
1.1.1 Definition 
Asphyxia features hypercapnia (increased levels of carbon dioxide in blood), 
hypoxemia (low oxygen concentration in arterial blood), and ischemia (diminished 
amount of blood perfusing the brain) (1). There is little agreement over the clinical 
definition of perinatal asphyxia, but there is consensus on the fact that no single 
feature alone should be used as definition. Two main characteristics of perinatal 
asphyxia are signs of cardiorespiratory and neurological depression, seen on a low 
Apgar score ( 3 at five minutes or later) (2) and metabolic acidosis. Metabolic 
acidosis is often defined as an umbilical arterial cord pH of < 7.0 and/or BE < -12 
mmol/l (UK) or < -16 mmol/l (US and Canada) (3-5). 
 
1.1.2 Incidence 
Due to the lack of coherence regarding definitions for perinatal asphyxia, it is 
difficult to make accurate estimates of the incidence. It also varies between 
developed countries and resource poor countries. In our part of the world the 
incidence for severe perinatal asphyxia (causing death or severe neurological 
impairment) is approx. 1/1000 live births, as opposed to 5-10/1000 live births in 
developing countries (6). According to the 2004 World Health Organization report, 
perinatal asphyxia causes 23% of the 4 million neonatal deaths worldwide (7). 
 
1.1.3 Aetiology 
Perinatal asphyxia may occur antenatal (20%), intrapartum (35%), intra- and 
antepartum (35%), and immediately postnatal (10%) (1). Causes are numerous, all 
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leading to impaired cerebral blood flow. Mostly this impaired cerebral blood flow 
occurs as a consequence of interruption of placental blood flow and gas exchange 
(e.g. umbilical cord compression, anaemia, bleeding, congenital cardiac and 
pulmonary anomalies, uterine hyperactivity, placental abruption, and birth trauma). 
The main risk factors for postnatal asphyxia are maternal opiates causing 
respiratory depression, obstructed airways or congenital sepsis (5, 6). 
 
1.1.4 Diagnosis and prognosis 
Perinatal asphyxia is diagnosed by a combination of symptoms and biochemical 
findings. Apgar score has been used to assess the newborn’s clinical condition since 
it was published by Virginia Apgar in 1953 (8). It is however a poor predictor of 
outcome, and should always be accompanied by other criteria (2). Other non-
specific signs of asphyxia include metabolic acidosis and meconium staining of the 
amniotic fluid.  
 
To diagnose perinatal asphyxia one should use the combination of low Apgar score, 
biochemical indicators (pH and BE), and clinical signs of hypoxic-ischemic 
encephalopathy (HIE) and multiple organ affection. HIE is graded according to a 
system introduced by Sarnat and Sarnat in 1976 (9), and modified by Levene et al in 
the 1980’s (10). It consists of three clinical stages, and is characterised by a pattern 
of evolving neurological signs over the first few days of life. The first clinical stage, 
mild HIE, is characterized by hyperalertness, staring, normal or decreased 
spontaneous motor activity, and a lower threshold for all stimuli. Stage two, 
moderate HIE, commonly includes seizures, it presents lethargy, hypotonia 
(typically a differential tone between upper and lower limbs with the arms being 
more hypotonic than the legs) and predominantly parasympathetic responses. The 
third stage, severe HIE, presents comatose infants with severe hypotonia, prolonged 
seizures, and absent primitive reflexes.  These infants mostly need ventilatory 
support due to respiratory failure. According to Roberton’s Textbook of 
Neonatology, the risk of death or severe handicap according to grade of HIE is 
1.6% for mild HIE, 24% for moderate and 78% for severe HIE (11).  
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1.1.5 Mechanisms 
Several mechanisms are involved in the brain injury caused by perinatal asphyxia 
(5, 12-14). A simplified schematic representation of the mechanisms involved is 
given in figure 1.  
 
The damage is inflicted in two stages; the initial and the secondary phase. The 
initial phase is characterized by energy failure and a decrease in cerebral 
microcirculation. This leads to initiation of free radical production by the 
mitochondrial redox chain, and to a depolarization of neuronal cells with influx of 
Na+, Ca2+ and Cl  ions, and water, which ultimately generates cytotoxic edema (14, 
15). The massive increase in free cytosolic calcium concentration is referred to as 
‘calcium overload’, and has been shown to activate enzymes that degrade 
phospholipids, proteins, and deoxyribonucleic acid (16, 17). The membrane 
depolarization also results in the release of glutamate into the extracellular space. 
Energy dependent reuptake mechanisms become compromised, and glutamate 
accumulates to excitotoxic levels, overactivating the N-methyl-D-aspartate 
(NMDA) receptors which again lead to influx of Na+ and Ca2+ (5, 15, 16, 18). The 
combination of energy failure, acidosis, calcium overload, glutamate release, free 
radical production, and lipid peroxidation ultimately leads to cell death (5). 
Between the initial and second phase of injury there is a free interval. In this 
interval, in cerebral tissue capable of recovery, the membranes are repolarized, and 
the energy metabolism is restored rapidly (5, 16, 17).  
 
The second phase of injury occurs from approx 6 to 48 hours after the initial 
incidence, and is characterized by a secondary energy failure (19). In the second 
phase glutamate is believed to play a larger role than in the initial phase, at least in 
global asphyxia (20). Glutamate excitotoxicity is seen as one of the major 
mechanisms for neuronal death after perinatal asphyxia (14, 15). Other major events 
in the second phase of injury are free radical production and release of nitric oxide 
(17, 20, 21). 
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Figure 1. Simplified schematic representation of the mechanisms involved in HI 
injury. 
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The immature brain is especially vulnerable to oxidative damage due to high 
concentrations of unsaturated fatty acids, high rate of oxygen consumption, low 
concentration of antioxidants, and high availability of free iron for direct production 
of free radicals through the Fenton reaction. It has been shown that free iron 
increases in hypoxic-ischemic brain injury, and that increased free iron in grey 
matter persists for several weeks after the hypoxic-ischemic event (15, 21). Other 
mechanisms that contribute to the damage seen in perinatal asphyxia are apoptosis, 
necrosis, and inflammatory reactions with release of cytokines and chemokines (12, 
13, 17). All these different mechanisms are linked together, and mitochondria play 
crucial roles in both the activation of apoptosis and the production of free radicals 
(21). 
  
Free radicals 
Free radicals are highly reactive atoms or molecules that contain one or more 
unpaired electrons. They can function as either reducing or oxidizing agents by 
donating or removing electrons from other molecules. The most important source of 
free radicals is the mitochondrial respiratory chain. Other sources are leucocytes, 
the hypoxanthine-xanthine oxidase system, and oxidation of arachidonic acid and 
catecholamines (22, 23). Free radicals are potentially harmful to cellular 
components, but normally exist in an equilibrium with innate cellular antioxidants, 
and are essential for fundamental cellular reactions and cell-cycle regulation (24). 
When biological processes lead to an increased free radical production, disturbing 
this equilibrium, it can result in oxidative damage to proteins, lipids, and DNA. Free 
radicals are part of the triggering of excitotoxicity and apoptosis (21).  
 
Apoptosis and Necrosis 
Apoptosis is an essential mechanism for maintaining homeostasis during 
development, and is often referred to as programmed/physiological cell death. It is 
an energy demanding process, and presents characteristic morphological changes 
such as condensation and fragmentation of the nucleus. There is no leakage of 
cytosol components and no inflammatory response. This is in contrast to cell death 
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caused by necrosis, which is induced by lack of energy. In necrosis the cells fail to 
maintain the normal electrolyte balance and ATP production, they swell and 
rupture. Cytosol components leak out into the surroundings and cause an 
inflammatory response. In neonatal hypoxia-ischemia it has been shown that both 
apoptosis and necrosis contribute to the subsequent damage (13, 25), and it has been 
found that the pathogenesis of hypoxic-ischemic brain damage is shifting from 
apoptosis to necrosis during brain development (26). 
 
Mitochondria are key regulators in the process of cell death through their capacity 
to release a number of pro-apoptotic factors from their intermembrane space, such 
as cytochrome c, caspase-2 and -9, and apoptosis-inducing factor (AIF).  
 
Caspases are a unique family of proteases that play an important role in the 
initiation and execution of apoptosis, with Caspase-3 acting as the key executioner 
(27). AIF triggers apoptosis in a caspase-independent manner, and can also induce 
caspase-activation (28, 29). There are at least three different pathways that lead to 
the execution of apoptosis: one caspase-independent pathway, involving AIF; one 
intrinsic pathway with apoptosome formation and caspase-9 cleavage, and one 
extrinsic pathway with binding of the Fas-ligand to its receptor and subsequent 
caspase-8 cleavage. The two latter both subsequently lead to caspase-3 activation, 
whereas AIF can induce caspase-activation by triggering the release of 
mitochondrial cytochrome c (18, 28, 29). 
 
1.1.6 Distribution of damage 
In mature infants the areas most often affected (i.e. most sensitive to hypoxic 
injury) are the cerebral cortex, hippocampus, cerebellum (purkinje cells), and the 
anterior horns of the spinal cord. Neuronal injury to basal ganglia is usually 
combined with injury to the thalamus, and is seen in approximately two thirds of 
asphyxiated term infants (1, 11). The distribution of white matter damage in the 
term infant is predominantly subcortical due to the distribution of the vascular 
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supply (30). The neurons show most damage while oligodendrocytes, astroglia and 
microglia mostly remain undamaged (20). 
 
Several animal studies have investigated the distribution of damage in different 
kinds of insults. Clapp et al subjected fetal sheep to transient episodes of partial 
cord occlusion for 1 minute every 3 minutes for 2 hours, and found exclusively 
white matter damage (31); whereas Myers and coworkers show in their primate 
model that hypoxia without acidosis causes white matter damage, while severe 
acidosis during the hypoxic insult causes basal ganglia damage (32).  
 
Periventricular leucomalacia is seen mainly in the immature/premature newborn, 
and is characterized by damage to the white matter dorsal and lateral to the lateral 
ventricle. It is increasingly rare after the 32nd week of gestation (20).  
 
The distribution of white matter damage in the mature and premature newborn is 
illustrated in figure 2. 
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Figure 2. MRI images illustrating damage to subcortical white matter with cystic 
lesions in the left image (white arrows, from Baenziger et al 1993 (33)); and 
damage to the periventricular white matter in the right image (black arrows, from 
Counsell et al 2002 (34)). 
 
 
 
1.1.7 Resuscitation and the use of oxygen 
Guidelines for resuscitation of neonates were last published in 2005. The American 
Heart Association and the International Liason Committee on Resuscitation both 
offer guidelines as shown in the flow chart in figure 3. They include observations of 
respiration, heart rate (HR), and skin color (35, 36). 10% of all neonates require 
assistance to start breathing at birth, and 1% need further assistance (35).When 
performed properly, positive-pressure ventilation alone is effective for resuscitating 
the majority of apneic or bradycardic neonates. For about 80% mask ventilation 
alone is sufficient, whereas a small number require endotracheal intubation (37). If 
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the heart rate remains < 60 bpm despite adequate ventilation for 30 sec, chest 
compressions are required, and should be carried out at a 3 : 1 ratio, with 90 
compressions and 30 breaths per minute. Drug therapy with adrenaline 
(endotracheal up to 0.1 mg/kg, intravenous 0.01 – 0.03 mg/kg; iv administration 
being the preferred route of delivery (38)), and volume therapy (isotonic saline 10  
ml/kg) should be considered if the HR does not respond after 30 sec of adequate 
ventilation and compression (35).  
 
Regarding oxygen the guidelines differ slightly: ILCOR does not specify the 
concentration of oxygen to be used at initiation of resuscitation. They do however 
state that there is no evidence to support or refute a change in the oxygen 
concentration that was initiated, once adequate ventilation is established, and 
recommend that supplementary oxygen should be considered for infants with 
persistent central cyanosis (36). The American Heart Association recommends 
supplementary oxygen to be administered whenever positive-pressure ventilation is 
indicated, but they do open for the use of room-air if supplementary oxygen is not 
available (35). 
 
The concept of hypoxia-reoxygenation injury through oxygen free radicals was 
introduced by Saugstad and Aasen in 1980 (39). Since then, the use of oxygen for 
resuscitation has been subject to extensive research. It has been demonstrated that 
room air is as efficient as 100% oxygen for neonatal resuscitation (40-42), and that 
100% oxygen has possible detrimental effects in clinical and experimental settings 
(43-46). Both a Cochrane database systematic review and a meta-analysis have 
concluded that there might be insufficient evidence to recommend room air over 
100% oxygen, or vice versa, but that a significant reduction in mortality in infants 
resuscitated with room air has been shown, and no evidence of harm demonstrated 
(47, 48). The trend worldwide is currently to reduce the oxygen concentrations used 
at resuscitation – the optimal concentration has however not been established.  
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Reproduced with permission from Pediatrics, May 2006, 117, e1029 – e1038. 
Copyright ©2006 by the American Academy of Pediatrics
Neonatal flow algorithm
HR indicates heart rate (shown in bpm). a Endotracheal intubation may be considered at several steps.
Figure 3.
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1.1.8 Therapy and intervention strategies 
To achieve satisfactory management of the asphyxiated newborn it is crucial to 
identify the infant at risk for evolving injury, to give supportive care to facilitate 
adequate perfusion and nutrients to the brain, to maintain glucose homeostasis, and 
to consider interventions to interfere with the process of ongoing brain injury (49).  
 
Supportive care includes ventilation (avoiding hypocapnia), blood pressure support, 
seizure treatment, fluid management and avoidance of hypoglycemia (49). The 
supportive strategies are often based more on empiricism than evidence. In fluid 
management, a strategy widely practiced is fluid restriction. This is however poorly 
studied; a Cochrane review from 2005 on this subject concluded that no studies 
could be included, and that one could only recommend fluid restriction to the 
seriously injured newborns with renal failure (50). Regarding the use of Dopamine 
in hypotensive newborns subjected to perinatal asphyxia, a Cochrane review from 
2002 concluded that only one study could be included in the review, and that it was 
thus impossible to make any recommendations (51). A Cochrane review published 
in 2001, and updated in 2007, on the use of anticonvulsants, concluded that there 
was not enough evidence to recommend the use of anticonvulsants for the 
prevention of severe neurodevelopment disability or to reduce mortality (52). 
  
Due to the fact that the secondary energy failure occurs from 6 to 48 hours after the 
initial event, the therapeutic window is estimated to be between 2 and 6 hours after 
the insult (5, 22).  Strategies aimed at reducing the extent of secondary brain 
damage involve therapeutic hypothermia, excitatory amino acid antagonists (xenon 
gas, magnesium sulfate), free radical scavengers (allopurinol, iron chelating agents), 
erythropoietin, calcium channel blockers (nicardipine) and the brain-derived 
neurotrophic factor (BDNF) (6, 49, 53, 54). In the following paragraphs we 
summarize some of the features of these interventional strategies.  
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Therapeutic hypothermia 
All the mechanisms for the neuroprotective effect of therapeutic hypothermia are 
not clear, but it is known that mild hypothermia (reduction of core body temperature 
by 3C) ameliorates the pathophysiological processes following asphyxia (55). 
Hypothermia reduces the release of excitatory amino acids and free radicals, 
reduces production of NO and leukotrienes, increases levels of IL-10, reduces 
apoptosis, prevents blood-brain barrier disruption and brain edema, and reduces the 
cerebral metabolic rate. It has been found to reduce damage in cortex, thalamus and 
hippocampus (49, 56-58).  
 
Therapeutic hypothermia is being assessed in several randomized trials in 
asphyxiated neonates, and so far the results are promising for the moderately 
asphyxiated neonate (59, 60). Only two reasonably large randomized clinical trials 
have so far reported 18 months follow-up data (61-63), presenting a significant 
reduction in death or disability. Regarding adverse effects, there is a risk of sepsis, 
thrombocytopenia, and arrhythmia, but so far no serious adverse effects have been 
reported in the conducted trials (56). Clinicians are now advised to follow 
guidelines from the conducted, or ongoing trials, if implementing hypothermia in 
clinical practice (60). 
 
 
Excitatory amino acid /Glutamate receptor antagonists 
Xenon gas 
Xenon is a nontoxic anesthetic gas. It reduces neurotransmitter release and 
antagonizes glutamate receptors (N-methyl-D-aspartate (NMDA)-subtype), and 
thus has neuroprotective effects (64). It also has an effect on the pathways involved 
in apoptosis, and seems to have antiapoptotic abilities (65). Xenon is an expensive 
drug, but has the advantage of being an established medication literally free from 
side-effects. More studies are currently being conducted (65).    
Magnesium sulfate  
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Magnesium sulfate is an antagonist to the glutamate receptors (NMDA), and blocks 
the neuronal influx of calcium (49, 66). It is used in perinatal medicine as a 
tocolyticum, and to prevent convulsions in preeclampsia. In this setting positive 
effects on outcome for premature infants have been found, which has lead to 
magnesium being assessed as a possible neuroprotective agent in perinatal asphyxia 
(67). Several studies have been conducted, both on animals and on neonates, with 
results showing both beneficial and non-beneficial effects (49, 67-69). Ichiba et al 
studied the use of magnesium sulfate in asphyxiated newborns, finding positive 
effects of a low dose over three days, both on short- and long-term follow up (70, 
71). Groenendaal et al however, had to abort their randomized trial due to marked 
hypotension (with a somewhat higher dose than Ichiba et al) (72). In the last trial 
from Ichiba et al they report respiratory failure and severe muscular hypotoni in all 
the treated neonates after infusion of magnesium. They avoided the hypotension 
problems by simultaneously infusing Dopamine (71). As stated by Perlman in his 
review of intervention strategies; “further research is necessary to determine the 
potential neuroprotective role of magnesium” (49).  
 
 
Free radical scavengers 
Allopurinol 
Allopurinol is a xanthine-oxidase inhibitor and free radical scavenger, and it has 
also been shown to have iron chelating abilities (73, 74). Van Bel and coworkers 
have shown positive effects on asphyxiated newborns (73), but the mentioned study 
had few included patients and was thus unable to show differences regarding death 
or neurological abnormality (6). A study by Benders et al (75) showed no improved 
short term outcome after severe birth asphyxia (Allopurinol given four hours after 
delivery), whereas a recent publication by Gunes et al (76) report improved 
neurologic and neurodevelopmental long-term outcome (12 months or more of age) 
when Allopurinol was given within two hours after delivery. Gunes et al do not 
provide information about the severity of the asphyxia in the follow-up data. 
Summarized there is not enough evidence to recommend clinical use of Allopurinol 
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for perinatal asphyxia at the present time. Maternal administration of Allopurinol in 
cases of fetal distress is currently being investigated (Van Bel and coworkers, 
presented at the 4th ‘Europe Against Infant Brain Injury’ (EURAIBI) meeting in 
Siena, Italy, April 2008). 
Iron chelating substances – Deferoxamine 
Non-protein bound iron (NPBI) is known to be liable to catalyze the formation of 
the hydroxyl radical through the Fenton reaction (77), and is thus thought to be a 
contributor to the damage seen in perinatal asphyxia. Deferoxamine is a well-known 
iron chelator, and research on animal models has shown that deferoxamine 
significantly lowers levels of NPBI in plasma and cerebral cortex.  It has however 
also shown negative circulatory effects on newborn, preterm baboons (53, 74, 78). 
Due to these findings caution is warranted with the use of this substance in newborn 
humans (53).  
 
 
Erythropoietin 
Erythropoietin (Epo)/recombinant erythropoietin (rEPO) has been subject to 
extensive research in animal models of experimental brain injury over the last 
decade. It has been shown to have neuroprotective effects, and modulates a wide 
range of processes, including progenitor stem cell development, cellular integrity, 
and angiogenesis (79). Epo has anti-inflammatory, antiapoptotic and neurotrophic 
abilities (80). In the neonatal brain Epo is released by astrocytes and triggers the 
release of dopamine, promotes neurogenesis and vasculogenesis, and stimulates 
glial proliferation (81). Trials are currently being performed to assess the most 
appropriate dosage in neonates at risk for hypoxic brain damage/developmental 
problems (SE Juul ‘A phase I/II trial of high dose erythropoietin in extremely low 
birth weight infants: pharmacokinetics and safety’. Oral presentation at the 48th 
annual meeting of the European Society for Pediatric Research, Prague, Czech 
Republic Oct. 6th-8th 2007). So far it seems to be well tolerated, and follow-up 
studies in rodents have shown no long-term negative effects (80).  
 
 26
Calcium channel blockers 
The massive increase in free cytosolic calcium concentration, the so-called ‘calcium 
overload’, that is seen in the initial phase of perinatal asphyxia, has been shown to 
activate enzymes that degrade phospholipids, proteins and DNA (16, 17). This 
mechanism has lead to the hypothesis that calcium channel blockers would reduce 
the damage found in hypoxic-ischemic brain injury (66), and experimental models 
have shown positive effects (82, 83). However Levene et al published a study in 
1990 on four infants with perinatal asphyxia, treated with the calcium channel 
blocker Nicardipine. The treatment was associated with clinically important 
hypotension (84). Following this, the recommendation has been to avoid calcium 
channel blockers in neonates and young infants because of significant adverse 
cardiovascular effects (49). 
 
 
Brain-Derived Neurotrophic Factor (BDNF) 
Neurotrophic factors are believed to play important roles in regulating neuronal 
connectivity in the developing central nervous system. BDNF is a neurotrophic 
factor highly expressed in the developing brain. It supports the survival and 
maintenance of specific populations of neurons, both in the peripheral and central 
nervous system (85, 86). Cheng et al (87) have shown a marked age-dependent 
neuroprotection by BDNF in rats. In neonatal rats they found a significant 
protection of brain tissue loss both when BDNF was given as pretreatment, and 
when it was given after the insult. The highest significance was found for the 
hippocampus. For adult animals however, no neuroprotection was shown. Similar 
findings of exogenous BDNF have also been demonstrated by others (88). BDNF 
has been found to have antiapoptotic abilities. It blocks activation of caspase-3, and 
decreases the up-regulation of other apoptotic proteins (phosphorylated c-Jun, 
cytochrome c) (89, 90).  BDNF does however not cross the blood brain barrier 
(BBB), and must be given intracerebrally/intraventricular (91). This limits the use 
in clinical contexts. Agents that increase levels of BDNF could however be useful.  
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1.2 Nicotine 
 
1.2.1 Historic data and general effects of nicotine 
Tobacco was introduced in Europe from the Americas in the late 15th and early 16th 
centuries by sailors returning to various ports in Europe. Nicotine is named after the 
tobacco plant Nicotiana tabacum, which in turn was named after Jean Nicot, a 
French ambassador to Brazil. He introduced tobacco into the court of Catherine de 
Medicis in 1560, and promoted its medical use. The first empiric studies of nicotine 
were conducted in the 1950’s (92, 93). Nicotine has mood-altering effects. It 
stimulates the release of several chemical messengers including acetylcholine, 
noradrenaline (norepinephrine), adrenaline (epinephrine), vasopressin, arginine, 
dopamine and beta-endorphin. Dopamine and glutamate are key neurotransmitters 
in the brain regarding nicotine’s ability to induce dependency (94). 
 
1.2.2 Negative effects of nicotine in the pre- and postnatal period 
Smoking during pregnancy has long been known to cause adverse effects on the 
fetus, and nicotine is believed to be the main agent for this. Animal studies on 
rodents and monkeys have shown that nicotine, in doses comparable to moderate 
smoking, up-regulates nicotinergic acetylcholine receptors (nAChRs) in the brain, 
and thus has an impact on brain development since these receptors are involved in 
cell replication and differentiation in the fetus (95-97).  A study on human neonatal 
brain tissue from aborted fetuses (<12 weeks) illustrates comparable effects of 
nicotine on neonatal human nAChRs (98). Ernst et al conclude in their review from 
2001 that a dose-dependent relationship between maternal smoking and low birth 
weight and spontaneous abortion has been shown, and that there are indications of 
impaired neurodevelopment and possible higher risk for psychiatric problems and 
substance abuse after prenatal exposure to nicotine (99). It has been proposed that 
fetal exposure to nicotine activates apoptosis, measured on increase in c-fos mRNA 
levels in neonatal rodents (c-fos is a nuclear transcription factor elevated in 
apoptosis and cell injury) (100). A study on ante- and postnatal administered 
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nicotine in piglets has showed increase in apoptosis measured on TUNEL staining 
and caspase-3 (101). A strong correlation has been found between maternal 
smoking, both pre- and postnatal, and sudden infant death syndrome (SIDS) (102-
105), and animal studies on both rodents and piglets have found nicotine to be 
responsible for this (106-109). Studies have also shown a correlation between 
maternal smoking and the development of asthma and respiratory symptoms in 
childhood, as summarized in two reviews by Cook et al (110, 111), and shown in a 
multi-centre study by Moshammer et al (112). Maternal nicotine exposure has been 
found to have an effect on lung surfactant system in newborn rats, suggesting that 
this could be of importance in the pathogenesis of impaired lung function in 
children exposed to intrauterine nicotine (113). 
 
1.2.3 Positive effects of nicotine 
Although the main focus on nicotine has been on negative effects, it has also been 
found to have several positive effects.  
 
Epidemiological studies have shown decreased incidence of Parkinsons disease, 
Alzheimers disease, and ulcerative colitis in smokers (114-116). Nicotine is thought 
to be the main contributor to these effects, and several animal and in vitro studies 
have been conducted to find the mechanisms by which these effects are carried out 
(117-121).  
 
Most studies on neuroprotective effects of nicotine look at nicotine administration 
prior to excitotoxic cell injury, inflammation, and hypoxia, but there are also a few 
looking into the effects of nicotine administered after an incidence (119, 122-128). 
This is the most interesting approach from a neonatal point of view, since there is 
seldom time or opportunity, nor a wish, to treat neonates at risk of perinatal 
asphyxia whilst intrauterine.  Nicotine has been, and is still being, investigated as a 
possible neuroprotective, antiinflammatory and antiapoptotic agent in several 
settings. The mechanisms by which these effects are believed to be carried out are 
discussed below: 
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Nicotine and nAChR 
nAChRs are a diverse family of ligand-gated ion channels, and binding of nicotine 
to their extracellular binding sites leads to influx of sodium and calcium ions (129). 
They are involved in a number of processes in the CNS. In neuronal development 
and survival they exert a trophic role, and the 7 subunit is implicated in several 
cellular processes like sensory perception, pain perception, body temperature 
regulation, neuroprotection, learning, and memory (130). Neuronal nAChRs are 
highly concentrated in the hippocampus, thalamus, and cortex. They play a role in 
enhancement of cognitive functions in the hippocampus and the cerebral cortex, in 
neuronal development in the sensory cortex, and in reward in the mesocorticolimbic 
system (131). 
 
nAChRs are considered the main binding site for nicotine, and extensive research 
has looked at nicotine’s binding to these, and the subsequent effects. The nicotine 
induced calcium influx after binding to the nAChR’s, decreases the ability of 
glutamate (and other excitotoxic agents) to increase calcium levels (132). The 
nAChR consist of several subunits, and research has found that nicotine’s effects on 
apoptosis and inflammation are carried out mainly through binding on the 7 and 
42 subunits (123, 124, 127, 133-140). This has been shown by using substances 
blocking these receptors, and subsequently antagonizing the mentioned effects.  
 
 
Nicotine and glutamate 
Glutamate release is seen as a part of the reward system, and glutamatergic 
neurotransmission is involved in the dependency-producing effects of nicotine (141, 
142). The effect of nicotine on glutamate has been investigated by Meshul et al 
(119) in an experimental rodent model. They show that the effect is dose- and time-
dependent, with higher doses, and long term treatment, inducing the release of 
glutamate; and smaller doses, and short term/subchronic (7 days) treatment, causing 
reduction in glutamate levels. Nicotine influences the release of dopamine in a time-
dependent way, with short term treatment causing increase in dopamine levels, and 
long term causing decrease (122, 143, 144). Increased levels of extracellular 
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dopamine have been reported to result in decreased striatal glutamate release (145, 
146). This might explain the effects of nicotine on glutamate. Furthermore, nicotine 
protects against glutamate induced neurotoxicity. This has been found to be 
mediated by nAChR’s, as shown by Sun et al (138), and Dajas-Bailador et al (124). 
 
 
Nicotine and calcium 
Nicotine has been shown to modulate glutamate induced increases in intracellular 
calcium (124, 147), and to reduce intracellular calcium concentration (138). This 
could be explained by the fact that nicotine has been found to activate calcineurin, a 
calcium dependent phosphatase, thus down-regulating the activity of L-type 
calcium channels (147). This might be one of the mechanisms by which nicotine 
exerts its neuroprotective effects. 
 
 
Nicotine and mitochondria 
Cormier et al (148, 149) have done experiments both in vitro and in vivo showing 
that nicotine has direct effect on mitochondria. They have found that nicotine binds 
directly to the complex I in the respiratory chain in the mitochondriae, antagonizing 
the NADH/H+ binding. This induces a decrease of free radical generation. Nicotine 
does not bind to the nAChR on the mitochondria, meaning that the mitochondria 
related effects of nicotine are nAChR independent.  
 
Further nicotine has been shown to inhibit mitochondrial swelling and cytochrome c 
release due to inhibition of the mitochondria permeability transition pore (mPTP). 
mPTP is involved in apoptosis through the release of cytochrome c, cytochrome c is 
a critical factor for triggering apoptosis through activation of the caspase cascade 
(121, 150). Findings by Xie et al support the assumption that there is a receptor-
independent neuroprotective effect of nicotine (121). These effects on 
mitochondriae could contribute to nicotine’s anti-inflammatory and anti-apoptotic 
effects.   
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Nicotine and free iron/the Fenton reaction 
The Fenton reaction produces oxygen radical species in the presence of free iron, 
and contributes to the formation of free radicals in hypoxic-ischemic brain injury of 
the neonate (77, 151-153).  
 
The Fenton reaction:  (1) Fe2+ + H2O2  Fe3+ + OH· + OH
(2) Fe3+ + H2O2  Fe2+ + OOH· + H+
 
 
 
 
Figure 4.  Nicotine forms complexes with free iron (Fe2+), here shown with binding 
to the pyridine nitrogen. 
 
 
Research on cellular level has shown that nicotine is capable of chelating free iron 
(154), and the findings of nicotine blocking the Fenton reaction is believed to be 
mainly due to this (120).  
 
In addition, the inhibitory effect of nicotine on the Fenton reaction leads to less 
oxidation of dopamine to the neurotoxic 6-hydroxydopamine (6-OHDA), and 
nicotine also inhibits the autoxidation of 6-OHDA, which leads to production of 
OH-, which again can produce H2O2, and trigger the Fenton reaction (117, 120). 
This is thought to be an important aspect of nicotine’s positive effects on 
Parkinson’s disease.  
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Further, nicotine has local effects on noradrenaline release (155), and Traver et al 
have shown that noradrenaline leads to a decreased concentration of ROS produced 
by the Fenton reaction (156). The inhibition of the Fenton reaction contributes to 
nicotine’s ability to reduce the concentration of free radicals in e.g. hypoxic-
ischemic brain injury. 
 
 
Nicotine and neurotrophic factors/BDNF 
Nicotine can increase the levels of some neurotrophic factors, like the nerve growth 
factor (NGF), the basic fibroblastic growth factor (FGF-2), and the brain-derived 
neurotrophic factor (BDNF). This effect is especially prominent in the hippocampus 
(118, 135, 157-159). Garrido et al show that nicotine treatment significantly 
upregulates NGF-expression (157). They have also demonstrated that in cultured 
spinal cord neurons exposed to arachidonic acid, nicotine pretreatment markedly 
protected against decrease in BDNF mRNA levels. However, nicotine did not affect 
the baseline BDNF mRNA expression (135). This indicates that nicotine exposure 
could prevent the decrease in BDNF levels that has been shown after hypoxia and 
inflammation in cell cultures. Nicotine’s effect on neurotrophic factors might be a 
part of the mechanisms by which nicotine carries out its anti-apoptotic effects.   
 
 
Nicotine and inflammation 
In recent years the expression ‘nicotinic anti-inflammatory pathway’, or the 
‘cholinergic anti-inflammatory pathway’ has emerged, indicating that the vagus 
nerve can modulate the immune response and control inflammation dependent on 
the 7nAChRs (160, 161). Nicotine has been proven more efficacious than 
acetylcholine at inhibiting pro-inflammatory cytokines like IL-1, IL-6, TNF and 
HMGB1 (high-mobility group box 1). The impact on TNF is carried out mainly 
through effect on the macrophages, which express 7nAChRs (128, 162). It has 
been shown that the effect of nicotine on the mentioned cytokines is a post-
transcriptional one, since there is no modulation of intracellular mRNA levels (128, 
163). Nicotine also has an impact on the secretion of pro-inflammatory cytokines by 
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inhibiting the NF-B (nuclear factor- B) pathway, probably by preserving 
cytoplasmatic levels of the inhibitor of NF-B (the IB inhibitor) (125, 160, 164).  
 
Regarding clinical use, ulcerative colitis is the only condition for which controlled 
trials have provided evidence of the therapeutic potential of nicotine (165). The 
therapeutic use of nicotine has been suggested for the treatment of several 
conditions like Tourette’s syndrome, Parkinsons disease, and Crohn’s disease (160). 
In sepsis nicotine has shown effect by significantly improving survival in an 
experimental setting, the main effect being binding to macrophages and inhibiting 
release of HMGB1 (128, 161). In an experimental study on renal 
ischemia/reperfusion injury nicotine has shown beneficial effects by inhibiting 
neutrophil infiltration, reducing TNF and HMGB1, and has also presented anti-
apoptotic abilities (166). Wittebole et al carried out an experiment on human 
subjects, studying the response to bacterial endotoxin or lipopolysaccharide (LPS) 
after pretreatment with nicotine or placebo (167). The results showed that nicotine 
pretreatment gave attenuated febrile response to LPS, and increased circulating IL-
10 and cortisol levels.  
 
In summary it has been shown that nicotine has an apparent impact on 
inflammatory responses, both peripherally and in the central nervous system.   
 
 
Nicotine and apoptosis 
Nicotine has been shown to act on the nAChRs and inhibit caspase activation 
(caspases 3, 7, 8 and 9), and it acts directly on mitochondria preventing the release 
of cytochrome c which is a caspase activator (121, 127, 136, 150, 166, 168). Sun et 
al (138) presented increase of the anti-apoptotic protein bcl-2, and decrease of the 
pro-apoptotic protein bax after 24 hours of nicotine treatment prior to hypoxia; this 
was proposed to be mediated through binding on nAChRs. Nicotine’s effect on 
neurotrophic factors is also believed to be one of the mechanisms by which nicotine 
exerts its anti-apoptotic effects (135, 158).  
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Nicotine and the sympathetic nervous system 
Nicotine is a known activator of the sympathetic nervous system. It increases the 
central nervous system sympathetic outflow; leads to catecholamine release from 
the adrenal medulla, from tissue stores, through stimulation of autonomic ganglia 
and peripheral chemoreceptors, and through local release from vascular nerve 
endings (94, 169). It increases systemic adrenaline (epinephrine) and noradrenaline 
(norepinephrine) in a complex dose-dependent manner (170, 171). Clinically this is 
observed as increased heart rate, blood pressure, and coronary blood flow (94). 
Very low doses are thought to act mainly on the CNS, whereas higher doses act 
more on the peripheral sympathetic nervous system. Extremely high doses of 
nicotine, however, induce peripheral ganglionic blockade, vagal afferent-nerve 
stimulation, and has direct depressor effects. Thus hypotension and slowing of the 
heart rate occurs when nicotine is administered in extreme doses (172). Several 
investigators have found that nicotine has local effects on noradrenaline release in 
cerebrum (155, 173, 174). This could contribute to the neuroprotective effects of 
low doses of nicotine (156). 
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2. Aims of the study 
 
 
Perinatal asphyxia is a major cause of mortality and morbidity, especially in the 
developing world. There is an ongoing search for interventional strategies that are 
safe, easy to use, cost-efficient, and most importantly – effective (5). Further, it is 
still debated what oxygen concentration should be used for resuscitation, although 
there is strong evidence against the use of 100% oxygen (175). We wanted to 
investigate the following issues:  
 
1. What would the effects of resuscitation with room air versus 100% oxygen 
be on the newborn brain after nicotine exposure? We chose to focus on 
morphological changes in cerebellum, striatum and cortex, hypothesizing 
that resuscitation with 21% oxygen in nicotine exposed animals would cause 
less damage to the neurons compared with 100% oxygen (paper I). 
 
2. What effect would pretreatment with nicotine have on the ability to endure 
hypoxia? We hypothesized that nicotine would have an effect on how long 
the piglets endured hypoxia; and that despite nicotine’s neuroprotective 
effects it would not be able to counteract 100% oxygen’s potentially harmful 
effect on the hypoxic piglet brain (paper I). 
 
3. Could some of nicotine’s neuroprotective effects be explained by systemic 
activation of the sympathetic nervous system? We hypothesized that 
nicotine in a low and moderate dose would not have any effect on plasma 
catecholamine levels (paper II). 
 
4. Would post-hypoxic treatment with nicotine in our model of neonatal 
hypoxic-ischemic brain damage have the same effects on free iron and 
glutamate as shown in vitro and in adult animal models, and thus indicate 
possible neuroprotective effects in asphyxiated neonates? (paper III)  
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5. How would nicotine affect BDNF and apoptosis in the hippocampus in the 
hypoxic newborn piglet when given after a hypoxic-ischemic insult? We 
hypothesized that nicotine would decrease the levels of AIF and caspase-3 
mRNA expression, increase levels of BDNF mRNA-expression, and 
increase levels of BDNF-protein in the hippocampus. This would imply a 
possible neuroprotective effect of nicotine infusions in hypoxic brain 
damage in the neonate (paper IV). 
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3. Materials and Methods 
 
3.1 The animal model 
 
Research on perinatal asphyxia is dependent on good models, as it is difficult to 
study the pathophysiology of this condition in humans. Over the last approximately 
40 – 50 years several models have been developed, involving non-human primates, 
puppies, immature rodents, lambs, and piglets (176). Much of our current 
understanding is based on studies in these models.  
 
An important issue in animal research is the difference in susceptibility to different 
interventions and treatments between species. For catecholamine response after 
injection of nicotine it has been shown that most species react in a similar manner 
(with a dose-dependent increase in plasma catecholamine levels) , with the 
exception of the fetal lamb, which has no response to nicotine infusions regardless 
of the doses used (177). This illustrates one of the caveats in research on animal 
models.   
 
The piglet model has advantages due to size and body weight, which matches that 
of a human newborn. This makes piglets easy to work with, and accessible to the 
same equipment as used in neonatal intensive care units. In addition, the anatomy 
and physiology of pigs are comparable to humans (178), and most importantly for 
the research on perinatal asphyxia – their brains show substantial similarities to the 
human brain. Brain growth and myelinization (179), brain maturation (180), and 
distribution of grey/white matter (181) are all comparable to that of human 
neonates. The degree of myelinization makes the newborn pig a better candidate for 
research on perinatal asphyxia than the non-human primate. Non-human primate 
newborns have substantially more mature brains at birth, with complete 
myelinization. This gives different distribution of damage in the primate model 
subjected to perinatal asphyxia (32, 181). 
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Compared to the human neonate, cerebral blood flow (CBF) in the newborn pig is 
elevated, and it has higher rates of cerebral metabolism (182). Studies aiming at 
finding the lower level of cerebral autoregulation (LLA) for newborn pigs have 
come up with values between 35 and 40 mmHg (183, 184). 
 
Different ways of inducing asphyxia/hypoxia-ischemia have been developed in the 
newborn pig. There are occlusion-models with occlusion of the common carotid 
arteries combined with low FiO2 concentrations that induces both global hypoxia 
and local ischemia (185, 186), and there are global hypoxia models with either 
constant or variable FiO2 (187-189). The global hypoxia models are able to induce 
ischemia when MABP reaches levels below LLA for longer periods of time. The 
animals in the global hypoxia models are monitored in different ways, with the 
variable FiO2 model using aEEG as an indicator of brain activity to regulate the 
amount of oxygen given, and the constant FiO2 model using MABP and BE to 
monitor the animals. The only comparative study done seems to favor the variable 
FiO2 model, finding that this gives the most predictable amount of injury (187).  
 
A drawback with the model used in the current study is the fact that the animals are 
subjected to global hypoxia at an age of 12-36 hours, meaning that they have 
already to some extent adapted to extra-uterine life. Further, in the present work the 
animals were normocapnic during hypoxia, which is a weakness since arterial pCO2 
is a strong determinant of CBF (190), and hypercapnia in perinatal asphyxia may 
influence the outcome by affecting both the general and cerebral circulation. There 
is large inter-individual variability in the newborn piglet model, causing problems 
regarding sample size and statistical analyses. 
 
 
3.2 Anesthesia  
 
Research performed on animals should always have as a prime incentive to provide 
optimal conditions for the animals, eliminating sources of stress, pain and general 
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discomfort. Thus the studies conducted in the present work had to be done in 
general anesthesia. This might lead to drugs acting as confounders, but care is taken 
using the optimal drugs and dosages to minimize this. It is however one of the 
drawbacks of results obtained in animal research.  
 
3.2.1 Procedure 
The animals were weighed and handled when awake, using heated towels and calm 
surroundings to minimize stress. They were then given gas as an introductory 
anesthetic as shown in figure 5.  
 
 
Figure 5. Administration of gas anesthetics. 
 
In paper I the animals were given Halothane 4% (Fluthane ZENECA). In papers II-
IV they were given Sevoflurane 5% (Sevorane, Abbott), reduced to 2% before an 
ear vein was cannulated. Halothane/Sevoflurane was then disconnected, and the 
piglets were given pentobarbital sodium 20 mg/kg and Fentanyl 50 μg/kg 
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intravenously as bolus injections. Anesthesia was maintained by a continuous 
infusion of Fentanyl (50μg/kg/h) and Midazolam (0.25mg/kg/h; IVAC P2000 
infusion pump). The dept of anesthesia was monitored by response to painful 
stimuli elicited by pinching between the toes, in addition to standard monitoring of 
heart rate and blood pressure. When considered necessary, a bolus of Fentanyl (10 
μg/kg) or Midazolam (1 mg/kg) was added. In paper III and IV the animals were 
given pancuronium bromide (0.1 mg/kg) to eliminate shivering that did not cease 
with additional anesthetics. Shivering is known to occur in piglets even if anesthesia 
is sufficiently deep, and could possibly have interfered with the experiment 
regarding cerebral oxygen consumption and the position of the microdialysis 
probes. A continuous i.v. infusion (saline 0.7% and glucose 1.25%, 10 ml/kg/h) was 
given throughout the experiments.  
 
3.2.2 Halothane/Sevoflurane 
In domestic large white pigs Halothane is known to have the ability to induce 
malignant hyperthermia and tetanus. It has however been shown that this effect is 
more prominent in older animals, and not as frequent in piglets (191). Further, 
Halothane depresses cardiovascular function and leads to decrease in blood 
pressure, heart rate, and CBF (191). These effects are time and dose dependent, and 
Halothane was only given for a few minutes in paper I.  In the following papers we 
changed to Sevoflurane administration. Sevoflurane has been found to be a safe and 
effective choice of anesthetics for children down to the age of 1 month (192), and it 
has been used in piglets and other animal models both in veterinary praxis and in 
research (193, 194). It has a cardio-depressive effect, but apparently not as strong as 
Halothane. Sevoflurane induces a slightly faster onset of anesthesia than Halothane 
(194), and was only given for a short period of time. 
 
3.2.3 Pentobarbital 
Pentobarbital, a well-known barbiturate in animal research, was used for the 
induction of i.v. anesthesia, and for the final overdose. Barbiturates are potent 
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cardiac depressants, with dose-dependent effects (195), but are generally well 
tolerated in pigs (196). They reduce CBF, intracranial pressure and the cerebral 
metabolic rate of oxygen (197, 198). Animal and in vitro studies have shown 
neuroprotective effects of barbiturates against hypoxic-ischemic brain damage (199-
201). The doses used in the current study were small, and were not expected to 
influence the results. 
 
3.2.4 Fentanyl 
Fentanyl was used for analgesia. Pigs have been shown to be relatively resistant to 
the effect of narcotic analgesics, and thus require larger concentrations of opiates 
than many other animal models and humans (202). This has been found explicitly 
for Fentanyl by Moon et al (203). Fentanyl can cause vasoconstriction of cerebral 
arterioles, possibly decreasing CBF (204, 205), and can increase cerebral fractional 
oxygen extraction (206). Further, it has been shown to be able to induce chest wall 
rigidity at high doses/rapid administration in humans (207). There appears to be no 
publications on this phenomenon in pigs, but it has been observed by our group. 
Care was taken during the present work to administer Fentanyl slowly, carefully 
monitoring the effect. 
 
3.2.5 Midazolam    
Midazolam as a sedative agent has proven effective in pig models, and has minimal 
effects on the cardiovascular system (208). It has however been demonstrated in a 
piglet model to increase cerebral fractional oxygen extraction – suggesting 
compromised cerebral perfusion and oxygenation (209). 
 
3.2.6 Pancuronium 
Pancuronium, a non-depolarizing muscle relaxant, has been investigated in a 
newborn piglet model by Easa et al. In their paper from 1993 they concluded that 
pancuronium administered to newborn piglets during normoxia, and during, or 
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after, hypoxia, while mechanically ventilated, does not alter the cardiovascular or 
pulmonary hemodynamic status (210). 
 
3.2.7 Implications 
Most of the anesthetics in the present work are capable of interfering with 
hemodynamics and cerebral blood flow. However, all the animals received the same 
drugs, so the anesthesia should have minor influence on the differences found 
between the groups. 
 
 
3.3 Microdialysis 
 
 
Figure 6. Newborn, anesthetized piglet in stereotactic frame with cerebral 
microdialysis probes. 
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Microdialysis has been used in research since the early 1970’s, initially solely in 
neuroscience (211). Currently it is also being used clinically, in a number of 
different tissues and organs (212). It is used for sampling of drugs, metabolites, or 
endogenous substances from fluids or the interstitial cell fluid of selected tissues. 
The principle behind microdialysis is a simple diffusion of low-molecular-weight 
substances down a concentration gradient from the extracellular fluid compartment 
to the dialysis fluid compartment within the microdialysis probe (213). The probe is 
constantly perfused with a perfusion fluid that mimics the composition of the 
surrounding medium, preventing excessive migration of molecules into or out of the 
periprobe fluid due to osmotic differences.  
 
The size of the molecules recovered is dependent on the ‘cut-off’ value of the 
probe, indicating the size of the holes on the dialysis membrane. It has been shown 
that only molecules about one fourth of the weight of the ‘cut-off’ value of the 
membrane are successfully recovered (212). In papers I and III we used a ‘cut-off’ 
value of 20 000 kDa.  
 
The analyte recovery is further dependent on the temperature, concentration 
gradient, and flow rate over the membrane. In general low flow rates results in 
larger recoveries than high flow rates. Low flow rates being rates from 0.5 – 5 
	l/min (212). We used a flow rate of 1 	l/min in our experiments. Analyte recovery 
can be either relative or absolute. Relative recovery is expressed in concentrations 
per volume; it describes the ratio between the concentrations in the dialysate to that 
in the periprobe fluid. Absolute recovery refers to the amount of compound in the 
dialysate per unit of time. Recovery will never be ‘absolute’ in the sense of directly 
reflecting the tissue/periprobe fluid concentration, it will always only be a fraction 
of the actual analyte concentration (212). It is however possible to determine 
recovery rate of the probes for the desired analyte prior to the experiment, giving 
the opportunity to calculate absolute values. This was not done in our experiments. 
 
The introduction of the probe should be done slowly to prevent cellular damage and 
bleeding. The insertion will cause a disruption of the BBB and an injury-mediated 
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release of neurotransmitters in the local tissue, and at least one hour should be 
allowed after insertion to reach baseline conditions (214).  
 
The analysis of microdialysate was done using the CMA 600 Microdialysis 
Analyzer (using enzymatic reagents and colorimetric measurements) for glycerol 
and glutamate, and non-protein bound iron was analyzed using spectrophotometry 
(using bathophenanthroline disulfonate (BPS) to chelate ferrous iron).  
 
 
3.4 Pathology 
 
Histopathologic visible ischemic cell change has been found to appear quite rapidly 
after ischemic brain damage, with microvacuolation of the neuronal cytoplasm 
being the first sign. These changes occur as early as 15 minutes after ischemia. The 
ischemic cell change is recognizable after 30-35 min, persisting up to 4 hours, with 
more pronounced damage being evident after 90 -150 minutes. Typically the 
watershed area of the cortex is injured first (215). The development of damage is an 
ongoing process for up to 24 hours after the insult. For severe damage the time-span 
for developing visible damage will be shorter than for less severe damage (181).  
 
Tissue for histopathological evaluation is stained using hematoxylin and eosin 
(H&E), an established method for evaluating morphological changes in neuronal 
tissue. Cerebral necrosis is defined by the presence of vacuolated neuropil, 
shrunken neurons with pyknotic nuclei, and eosinophilic neurons. In cerebellum 
necrosis is defined by the presence of necrotic Purkinje cells with eosinophilic 
cytoplasm. We performed additional immunohistochemical staining with MAP-2 to 
confirm the areas of damage found with H&E staining.  
 
MAP-2 (microtubule-associated protein 2) is an important cellular component of the 
neuronal cytoskeleton. It is a major component of all neurons and is highly 
localized to the somato-dendritic compartment. MAP-2 has been shown to regulate 
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the assembly and stability of neuronal microtubules, and has been suggested to help 
in regulating a balance between rigidity and plasticity in neuronal processes. It has 
been found to be a sensitive marker for ischemia in neurons and is down-regulated 
in this form of injury, with changes detectable as early as three minutes after 
ischemia (216, 217).  
 
In paper I the animals were observed for 150 minutes after hypoxia/resuscitation, 
before receiving an overdose with pentobarbital. Tissue blocks from striatum, 
cortex and cerebellum were stained with H&E. The evaluation was done blinded, 
and damage was classified as present (+), or not present (-). MAP-2 
immunohistochemistry was used to confirm areas of ischemic cell damage. Due to 
the short time of observation, the damage was classified as ‘early necrosis’. 
 
In paper IV the animals were observed for four hours after hypoxia, before 
receiving an overdose with pentobarbital. Tissue blocks from striatum, cortex and 
cerebellum were stained with H&E. The evaluation was done blinded, and damage 
to striatum and cortex was divided into five different categories: 0 = no damage 
found; 1 = 10% of the tissue damaged; 2 = 20-30% damaged; 3 = 40-60% 
damaged; and 4 = >75% of the tissue damaged. MAP-2 immunohistochemistry was 
used to confirm areas of ischemic cell damage. For the cerebellum the 
hypoxic/ischemic changes were defined by the presence of necrotic Purkinje cells 
with eosinophilic cytoplasm. In each case the number of eosinophilic Purkinje cells 
was counted in one section from the vermis of the cerebellum. Damage was 
classified as: 0 = no necrotic Purkinje cells; 1 = <50 cells; 2 = 50-150 cells; 3 = 
>150 cells. 
 
The histopathological evaluations have the drawback of having been conducted not 
by a standardized machine, but by a human being. They were also done only by one 
pathologist, which could raise question regarding reproducibility. The MAP-2 
staining contributed to confirm the findings on H&E staining, and the evaluations 
were done blinded, by an experienced pathologist. We thus believe that they are 
comparable, reproducible, and of good quality. 
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3.4.1 Immunohistochemistry 
Immunohistochemistry is a combination of an immunoreaction identifying a 
specific protein/substance in a selected tissue, and the detection of that reaction 
using light microscopy. The principle is binding of an antibody to an antigen in the 
tissue-sample, either direct (using a labeled primary antibody) or indirect (with 
labeled secondary antibodies). The staining can be performed with immunoenzyme-
techniques, or immunofluorescence. Immunofluorescence requires specialized 
microscopes for evaluation, and lack the easy comparison with the morphology in 
the tissue sample. For detection the antibody is either labeled with a fluorescent 
(Fluorescein, Rhodamine), or an enzyme that is linked with a chromogenic substrate 
to develop color (e.g. Avidin-biotin peroxidase (ABC) and Diaminobenzidine 
(DAB)).  
 
For the fixation of the tissue both formalin and freezing can be adequate, but require 
different preparation before adding of the antibodies. Formalin fixation and paraffin 
embedding leads to ‘masking’ of the antigens, and ‘demasking’ can be achieved by 
different enzymatic or denaturing procedures that break up the protein meshwork. 
Procedures often used are: proteolytic enzymes, chemical denaturation, and boiling 
(microwave). (Reference: ‘Methods in biomedical research’, lecture by Per 
Brandtzæg (RH) august 2006 on ‘Immunohistochemistry and 
immunocytochemistry’). The evaluation of immunohistochemistry is often done by 
computers with special software. We did not have such a machine when evaluating 
our results from paper IV, but the counting was done blinded, and followed a 
predefined setup. A drawback of working with antibodies is the variation in 
specificity of the antigen binding. Both the antibodies used in the present work were 
of satisfactory specificity. MAP-2 antibodies are highly specific, and have no 
known cross-reactions according to the manufacturer. The specificity of the BDNF 
antibody used in paper IV was 95%, with 5 % cross-reactivity with rh-NGF and 
rr-NGF.    
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3.5 Real time Polymerase Chain Reactions 
 
The polymerase chain reaction (PCR) was invented by the 1993 Nobel laureate 
Kary B. Mullis in 1985. It uses a polymerase to catalyze the regeneration of DNA 
with a chain reaction that is repeated over and over to exponentially amplify the 
target DNA. This allows genetic material to go from scarce to abundant for 
analysis. Real time PCR amplifies a specific target sequence in a sample, 
monitoring the amplification process using fluorescent technology. The 
fluorescence signal increases in direct proportion to the amount of PCR product in a 
reaction during each cycle (in real time) as opposed to the conventional method 
where the product is detected at the end point. This increases the sensitivity of 
detection of the PCR product, leading to better accuracy and reproducibility (218). 
The major disadvantage to real time PCR is the requirement of expensive 
equipment and reagents; another drawback is that the method is relatively sensitive 
to minor variations in reaction components, thermal cycling conditions, and 
mispriming events during the early stages of the reaction. This can lead to large 
changes in the overall amount of amplified product. When handled correctly it is 
however a sensitive, reproducible and efficient method (219).  
 
 
3.6 Catecholamine measurements 
 
Catecholamines can be measured in urine, plasma, and in platelets (220). Urine-
catecholamines are normally measured after collecting urine for a longer period of 
time, and is thus unsuitable for analyzes of changes happening over shorter time 
periods. Measurements of catecholamines in plasma is an established method, but 
because catecholamines in blood are easily degradable, it is required that the blood 
samples are collected in pre-treated containers (e.g. EGTA-gluthatione) kept on ice, 
and centrifuged immediately after sampling. There are different methods for 
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analyzing catecholamines in plasma (221). One of the well-established methods is 
high performance liquid-chromatography (HPLC). In paper II plasma noradrenaline 
(NA) and adrenaline (A) were determined by HPLC with a reverse phase column 
and glassy carbon electrochemical detector (Agilent Technologies, Colorado, USA), 
using a commercial kit (Chromsystems, München, Germany). The intra- and 
interassay variations were 3.9% and 10.8% for NA, and 13.3% and 14.8% for A 
respectively; the detection limit was 5.46pmol/l. Sources of error in this method are 
suboptimal storage of the vaccutainer containers and of the samples; and wrong 
treatment and optimizing of the samples. Another source of error is use of 
paracetamol, which can give a false positive NA value. Paracetamol was not used in 
the current study. Both the containers and the samples were treated as 
recommended (kept on ice and frozen immediately after centrifugation). 
 
We are using pmol/l, whereas in the literature values are often referred as pg/ml. 
For results obtained by the same method (HPLC) this is easily converted by the 
following formulas: 
 
Noradrenaline (MW 169.18 g/l):  pg/ml · 5.9 = pmol/l   (0.16918 pg/ml · 5.9 
 
1) 
 
Adrenaline (MW 183.2 g/l):  pg/ml · 5.4 = pmol/l   (0.18320 pg/ml · 5.4 
 
1) 
 
 
3.7 Measurements of nicotine concentrations  
 
Nicotine analyzes are frequently used in smoking-related research, although the 
measurement of coitinine, the metabolite of nicotine, is more commonly used for 
assessment of tobacco-intake. We measured nicotine concentrations to assess our 
administered doses, in order to compare these to concentrations previously reported 
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and to concentrations seen in smokers (to compare with levels that are known to be 
non-toxic). Gas chromatography-mass spectrometry (GC-MS) is the most common 
way of measuring nicotine (222, 223).   
 
Nicotine analyzes in the current work were done using gas chromatography-mass 
spectrometry (GC-MS), the analyzes were carried out at the Norwegian Institute of 
Public Health, Division of Forensic Toxicology and Drug Abuse. The lower limit of 
detection was 0.05 μM. The drawback of this method is the lack of standardization. 
It is not routinely performed, and is referred to as an experimental method. It has 
however been performed quite often in the Forensic Toxicology lab, and the results 
are therefore seen as reliable and reproducible.  
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4. Main results of the study 
 
 
Paper I 
 
Resuscitation with 21% or 100% oxygen in hypoxic nicotine pretreated 
newborn piglets. Possible neuroprotective effects of nicotine.  
 
Animals pretreated with nicotine endured a significantly longer time of hypoxia 
before reaching defined endpoints (BE < -20 mmol/l and/or MABP  20 mmHg), 
compared to animals treated with saline prior to hypoxia (103.8 ± 28.2 min vs. 66.5 
± 19.5 min, p = 0.035). There was early cerebral necrosis (striatum and cortex 
combined) in 6 of 8 animals in the nicotine pretreated hypoxic group resuscitated 
with 100% oxygen, and 1 of 7 animals in the nicotine pretreated hypoxic group 
resuscitated with 21% oxygen (p=0.036, 95% CI 0.0 – 0.693). There was a 
significant difference between the two mentioned groups regarding striatal (0 of 7 
vs. 5 of 8, p=0.026) early necrosis, but not for cortical (1 of 7 vs. 5 of 8, p=0.063) 
early necrosis.  
We observed a decrease in early necrosis both when combining striatal and cortical 
necrosis, and for striatal necrosis alone in the animals resuscitated with room air 
compared to 100% oxygen; for cortical necrosis there was a trend towards less 
necrosis in the animals resuscitated with room air. These findings support other 
studies in the conclusion that 100% oxygen should not be used routinely for 
neonatal resuscitation. The results further suggest a possible neuroprotective effect 
of nicotine. 
 
 
Paper II 
 
Nicotine in a small to moderate dose does not cause a significant increase 
in plasma catecholamine levels in newborn piglets. 
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Newborn piglets with comparable levels of plasma catecholamines at baseline were 
randomized to three different groups, receiving nicotine-infusions (for 1 hour) with 
one of three concentrations of nicotine. Adrenaline/Epinephrine increased 
significantly in the group treated with 1000μg/kg/h nicotine (p=0.019), but not for 
the groups treated with 130 or 260μg/kg/h nicotine. There were no significant 
increases in noradrenaline/norepinephrine in either of the groups. Thus we find that 
nicotine in a small and a moderate dose does not generate a significant increase in 
plasma catecholamine levels, whereas a higher dose significantly increases plasma 
adrenaline values. This confirms the dose dependent effect nicotine is believed to 
have on the sympathetic nervous system. These results suggest that the positive 
effects of nicotine found in studies with nicotine administered in these 
small/moderate doses, can probably not be explained by the systemic release of 
catecholamines. 
 
 
Paper III 
 
Effects of nicotine infusion on striatal glutamate and cortical Non-
Protein Bound Iron in hypoxic newborn piglets.  
 
Microdialysis was used to sample dialysate from striatum and cortex at baseline, 
after hypoxia, and during the observation period. For striatal glutamate there was a 
significant rise from baseline to the end of hypoxia for all the animals (p < 0.001, 
1.8 ± 0.35 vs. 38.3 ± 5.79μmol/l). The animals treated with nicotine 130μg/kg/h 
presented a significant decrease in glutamate (68% decrease from end of hypoxia) 
compared to the saline treated animals (17% increase from end of hypoxia) at d1 (2 
hours after hypoxia) (p = 0.002), but not for d2 (end of experiment, 4 hours after 
hypoxia).  
 
From baseline to the end of hypoxia there was a significant rise in NPBI in cortex in 
all the animals (p < 0.001, 0.7 ± 0.04 vs. 1.1 ± 0.08μmol/l). There was a decline in 
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cortical NPBI values at d1 for all the groups except the saline treated group (31% 
increase from end of hypoxia), significantly so for adrenaline (32% decrease) and 
nicotine 130μg/kg/h (25% decrease from end of hypoxia) (p = 0.003 and p = 0.013, 
respectively). There were no significant differences at d2.  
 
These findings suggests that nicotine can decrease striatal glutamate levels after a 
hypoxic-ischemic insult, supporting the hypothesis that short term, low dosed, 
nicotine treatment decreases glutamate levels. The decline in extracellular NPBI in 
cortex supports the findings from in vitro studies, that nicotine chelates free iron. 
The one hour infusion of low dose nicotine had significant effects two hours after 
hypoxia, indicating an effect on the early stages of the secondary phase of injury. 
One could speculate if a prolonged infusion could give a longer lasting effect. These 
findings support the hypothesis that nicotine has similar effects in a neonatal model 
of hypoxic-ischemic brain damage as shown in previous experimental settings, 
suggesting possible neuroprotective effects of nicotine for this cohort.  
 
 
Paper IV 
 
Nicotine increases the expression of Brain-Derived Neurotrophic Factor 
mRNA and protein in the hippocampus of hypoxic newborn piglets. 
 
Real time PCR was used to assess the expression of BDNF, AIF and caspase-3 
mRNA in the hippocampus, and immunohistochemistry was used to assess the 
amount of BDNF protein in the dentate gyrus of the hippocampus.  
 
Newborn piglets treated with nicotine 130μg/kg/h presented significantly more 
BDNF mRNA (p = 0.029) and protein than animals treated with saline (33 ± 14 vs. 
17 ± 8% positive cells, p = 0.009). Regarding AIF and caspase-3 mRNA there were 
no differences between the groups, and we speculated that this might be due to a too 
short observation period, and that we thus could not draw any conclusions on 
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nicotine’s effects on apoptosis after this experiment. We concluded that nicotine 
130μg/kg/h, infused over one hour after global hypoxia in neonatal piglets, 
increased levels of both BDNF mRNA and protein in the hippocampus. This might 
imply neuroprotective effects of nicotine in asphyxiated neonates.    
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5. General discussion 
 
5.1 The need for intervention. 
 
Despite extensive research on prevention and intervention, perinatal asphyxia 
remains one of the major contributors to perinatal mortality and morbidity (6, 7). 
Interventional strategies should aim at ameliorating the secondary brain injury, be 
easily administered, effective when given after delivery, and cost-effective. So far 
the most promising intervention is therapeutic hypothermia (56). Hypothermia has 
however not proven able to fully prevent the secondary damage inflicted, and 
therefore there is still an ongoing search for further options. As mentioned in the 
introduction there are several groups investigating different agents, with 
erythropoietin and xenon gas as examples of two promising strategies. The future 
solution might very well be a combination of several agents, with synergistic 
effects, as it has already been shown in rodent models for the combination of 
hypothermia and xenon gas (65, 224). There is a definite need for interventional 
strategies for this group of patients, to improve prognosis and lower morbidity. 
 
5.2 The role of oxygen 
 
The most common intervention in newborns is the assistance to start breathing, 
which is required in 10% of all neonates. The guidelines for resuscitation do not 
give strict advice concidering what oxygen concentration to use when ventilatory 
assistance is required, and this is an area of ongoing research and debate. Recent 
reviews and original articles have added further knowledge to the debate, disputing 
the use of 100% oxygen, both in resuscitation and in the neonatal intensive care unit 
(44, 175, 225, 226). It should be kept in mind that oxygen is a drug, and should be 
administered as such, upon indication, and in a dose-response related manner. 
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5.3 Nicotine as an interventional strategy 
 
This work has aimed at investigating nicotine as a possible neuroprotective agent in 
hypoxic newborn piglets. Nicotine is an unconventional candidate for 
neuroprotection in neonatal medicine, since it is mainly associated with maternal 
smoking and the subsequent impact on neonatal morbidity and SIDS. Nicotine has 
however in the last two decades proven to be an anti-inflammatory and anti-
apoptotic agent in several studies in animal models, on cell-cultures, and even in 
neonatal animal models (122, 137). As stated in the introduction, under mechanisms 
of perinatal asphyxia (chapter 1.1.5), an extensive cascade of events occurs during 
and after a hypoxic-ischemic event. Nicotine has potential effects on several of 
these, indicating possible potential in limiting and preventing the damage inflicted.  
 
Nicotine has impact on the free radical production by acting both directly on the 
mitochondria (121, 148), which are crucial in this process, and on the Fenton 
reaction (154); decreasing the production of free radicals. Another crucial event in 
the cascade is the calcium overload (16). Nicotine has effect on the levels of 
calcium, and has been found to reduce intracellular calcium concentrations (138), 
indicating a possible effect in this phase. The glutamate release is a major event in 
the sustaining of influx of electrolytes and water into the cells, causing cytotoxic 
edema and subsequently cell death. Nicotine has been found to lower levels of 
glutamate (119), and might have a positive effect because of this. The degree of 
apoptosis could be lowered due to nicotine’s anti-apoptotic effects (138, 150), and 
this way nicotine could prevent some of the secondary injury inflicted after 
perinatal asphyxia. Regarding the inflammation seen in perinatal asphyxia nicotine 
could have positive effects. Much research has been done on the so-called ‘nicotinic 
anti-inflammatory pathway’, and nicotine has been found to have anti-inflammatory 
effects both peripherally and centrally (160, 227). Finally there is the effect of 
nicotine on neurotrophic factors (118, 159). This could be of major impact, 
especially since BDNF, which has proven to be an effective agent when 
administered locally (87), can not cross the BBB, and thus is not suitable for 
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treatment in neonates. Nicotine leads to an increase in BDNF, and this could 
contribute to neuroprotective effects of nicotine in this group of patients.   
 
5.3.1 Age-related differences in nicotine effect 
Concern has been raised regarding difference in mechanisms of effect in adult and 
neonatal models, with Laudenbach et al (137) finding that stimulation of the 
nAChR 7 subunit in neonatal mice is detrimental, whereas several of the studies in 
adult models find this receptor to be the main source of effect (160, 228). 
Laudenbach et al do, however, find beneficial effects of stimulation of the 42 
subunit. This is the same subunit that is thought to be the most common within the 
mammalian brain, greatly contributing to neuroprotection in striatal and cortical 
neurons (147, 159, 229). To our knowledge there has only been one study 
conducted on specific receptors in neonatal models, and this should clearly be 
investigated further.  
 
5.3.2 Dose-related differences in nicotine effect 
Nicotine’s effects are dose-dependent (227, 230). There are two main theories on 
why the higher doses show opposite effects to the lower ones. One is the possible 
desensitization of the nAChR’s (229). The other is that high doses of nicotine may 
allow too much calcium into the cell through the nAChR’s and exacerbate cell 
death (132). Studies published on nicotine present a large variety of doses and 
dosing regiments. In general one could say that they show opposite effects of high-
dose vs. low-dose and acute/subchronic vs. chronic nicotine administration. There 
are however differences in the perception of what a ‘low dose’ is, and what should 
be classified as acute and chronic treatment. We here summarize some of the 
findings and the differences in dosing. 
 
 Barros et al (230) gave adult rats nicotine 0.3 or 1.0 mg/kg twice daily for nine 
days and found increased oxidative stress and DNA damage in the hippocampus of 
the group treated with the higher dose. Bhagwat et al (231) looked at a similar dose 
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(1.6mg/kg/d for 10 days), finding increased oxidative stress in adult rat brain, liver, 
and lung. Ryan et al (229) treated adult mice for 14 days with low doses (defined as 
0.75 and 1.5mg/kg/d), or high doses of nicotine (defined as 3.0 and 30.0 mg/kg/d); 
or with a single dose of 1.0mg/kg. They presented protective effects (preventing 
neurodegeneration) of the acute treatment and of chronic treatment in low doses. 
The higher doses failed to show any neuroprotection. The doses used in studies 
showing neuroprotective effects range from 0.35mg/kg as a single dose in adult rats 
(125); 0.1 mg/kg/h for 12hours x 3 in Laudenbach et al’s study in neonatal mice 
(137); 2.3 mg/kg/d (0.2μmol/kg/h) for four weeks administered to the mother of 
suckling asphyxiated neonatal rats (122); to the rather high dose of 7mg/kg as a 
single dose in adult rats in the same study where they found the effects of the low 
dose (0.35mg/kg) (125). This illustrates the wide range of dosing, and dosing 
regiments, highlighting the difficulty in finding the optimal dose for nicotine as a 
neuroprotective agent. Our results indicate that a dose of 0.26mg/kg/h for one hour 
might be too high to have neuroprotective effects in a neonatal piglet model of 
hypoxic-ischemic brain damage. We also present data suggesting that it might be of 
advantage to give the nicotine infusion over a longer time-period than one hour. 
 
5.3.3 What is new in our research on nicotine  
To our knowledge this is the first work done on neuroprotective effects of nicotine 
in neonatal piglets, and shows that our model can be useful in this kind of research. 
Despite differences between adult and neonatal receptor response to nicotine 
administration, as shown by Laudenbach et al (137), we have found indications of 
neuroprotective effects in our model. We have used a lower dose and a shorter 
dosing regime than the comparable studies, and have thereby contributed to the 
discussion regarding what dose to use. We have found better effects of 0.13 vs. 0.26 
mg/kg/h, and we have also shown that it is unlikely that the systemic activation of 
the sympathetic nervous system contributes to the positive effects. 
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5.4 Considerations  
 
Animal models are of great importance in medical research, but have the drawback 
that they are not directly translational to human situations. Findings in other species 
can never be directly transferred to humans, and models will always be 
simplifications of very complex situations.  
 
Our animals received anesthetics that could aggravate the situation, but also in some 
cases improve it (i.e. barbiturates and their neuroprotective abilities (200)).  
 
Properly assessing neuroprotective treatments requires time. Survival studies would 
have given valuable information of the actual effects over a longer time span. With 
the current model that was not possible, and we can therefore only speculate 
regarding the long-term effects of treatment. We do however consider our model to 
be a good model for studying the current hypothesis, due to the advantages of 
comparable anatomy, brain-maturation, physiology and response to hypoxia 
between newborn pigs and humans (178-180).  
 
Drawbacks of the current model are for one the fact that our animals were to some 
extent already adapted to extra-uterine life when exposed to hypoxia; and also the 
fact that the initiation of intervention in papers III and IV was five minutes after the 
end of hypoxia, which would be difficult in a clinical situation.  
 
Although data from animal models of asphyxia do not necessarily fully mimic the 
human perinatal conditions, they can hopefully provide us with important 
understanding of mechanisms of injury and interventions following asphyxia. And 
we thus hope that our findings, despite shortcomings, can contribute to the 
understanding and further research on asphyxia, and the possible advantages of 
nicotine infusion. 
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5.5 Implications for further research 
 
This study raises several questions regarding the potential use of nicotine in the 
neonate exposed to oxygen deprivation. Future research should aim at mapping 
more of the mechanisms behind its neuroprotective effects in the neonatal brain, 
with a special interest in the different subunits of nAChR’s and the subsequent 
effects of their activation. An important issue is the observation time. To properly 
assess intervention in perinatal asphyxia, survival studies are required.  
 
Our study has given an indicator of doses, but dose-response studies are needed. 
Further research should be done with lower doses than ours, since the levels of 
blood nicotine concentrations differ extensively between our study and that of Chen 
et al (122) (65 ± 5 vs. 5.4 ± 0.7 ng/ml). They show beneficial effects in asphyxiated 
neonatal male rats. Our study has also shown that a longer infusion time could be 
beneficial, since the one hour infusion failed to give a prolonged effect on NPBI 
and glutamate (paper III).  
 
There is clear evidence that there is a difference in how the genders respond to 
hypoxia. Renolleau et al (232) show that in male animals apoptosis is 
predominantly carried out through the caspase-independent pathway (AIF), whereas 
in female animals apoptosis is carried out through the activation of caspase 3. This 
implies that all neuroprotective strategies should be studied for the two sexes 
separately.  
 
5.6 From animal studies to clinical use 
 
In adults nicotine has been, and is currently being, tested in clinical settings. It is 
showing promising effects in Parkinsons disease (233) and ulcerative colitis (165). 
For ADHD a resent clinical trial found improvement in cognitive performance 
following nicotine administration in young adults (234). Wittebole et al found 
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positive effects on the response to endotoxin in young adults who were pretreated 
with nicotine (167).  
 
Most studies on nicotine concentrate on the nAChR’s. If nicotine’s effects were 
carried out solely through effect on these receptors, it would make more sense to 
use specific nAChR agonists as therapeutic agents rather than nicotine. As stated in 
the introduction, nicotine does however carry out its effects in more ways than 
receptor stimulation, and it therefore seems reasonable to focus research on nicotine 
rather than nAChR agonists, as long as there is no evidence that the effects sought 
after come from receptor stimulation alone.  
 
Clinical studies of nicotine as a neuroprotective agent in neonates will not be 
feasible until more research has been done on dose-response, mechanisms, and on 
long-term effects.   
 
Regarding the use of oxygen in neonatal resuscitation, the findings in this study 
adds to the evidence against use of 100% oxygen in resuscitation of the neonate. 
Reminding us that oxygen is a drug, which should be used with consciousness and 
caution. 
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6. Conclusions 
 
1. Resuscitation with 21% oxygen inflicted less necrosis than 100% oxygen, 
supporting other studies in the conclusion that 100% oxygen should not be 
used routinely for neonatal resuscitation (paper I). 
 
2. Nicotine administered prior to global hypoxia enhanced newborn piglets’ 
ability to endure hypoxia. Despite nicotine’s neuroprotective abilities it was 
not able to counteract the harmful effects of resuscitation with 100% oxygen 
(paper I). 
 
3. Protective effects of nicotine in doses of 130μg/kg/h and 260μg/kg/h can 
probably not be explained by a systemic activation of the sympathetic 
nervous system, since infusions with these doses did not present any 
increase in plasma catecholamines (paper II).  
 
4. Treatment with nicotine 130μg/kg after global hypoxia induces a significant 
decrease in striatal glutamate and cortical NPBI two hours after a hypoxic-
ischemic insult. Our findings support the hypothesis that nicotine has similar 
effects in a neonatal model of hypoxic-ischemic brain damage as shown in 
experimental settings with adult animals. This suggests possible 
neuroprotective effects of nicotine in neonates (paper III).  
 
5. Treatment with nicotine 130μg/kg/h after global hypoxia increases the 
expression of BDNF mRNA and protein in the hippocampus. In our model, 
with an observational period of four hours, it does not have an impact on 
either the caspase-independent, or –dependent pathways. These results 
suggest a possible neuroprotective effect of nicotine in the hippocampus of 
neonates through the up-regulation of the neuroprotective BDNF (paper IV). 
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In summary, our findings indicate possible neuroprotective effects of nicotine 
administration in asphyxiated newborns and show that resuscitation with 100% 
oxygen may cause increased cerebral necrosis.  
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